Verifying SPARCL Performance on the CLARIOstar Equipped for Reading at Time of Injection

BMG LABTECH GmbH

Notice

The provider currently does not offer this white paper for download. You can find additional white papers in our white paper directory.

SPARCL refers to an immunoassay that does not require washing steps. An analyte in solution is detected by binding two antibodies: one is coupled to horse radish peroxidase (HRP), the other is coupled to the HRP substrate Acridan.
In presence of the analyte, binding of both antibodies brings enzyme and substrate into proximity. The enzymatic reaction is started by the addition of H2O2, which immediately produces a light proportional to the amount of analyte. Thus, SPARCL assays require to be read at the same time as injection of the trigger solution.
The CLARIOstar® microplate reader equipped with the dedicated H3 injection needle for simultaneous injection and reading fulfils this task. The analyte IgG was detected down to a concentration of 45 ng/ml in 96 wells and down to 15.6 ng/ml in 384 well format. BMG LABTECHs MARS analysis software facilitates subsequent calculation of analyte concentration.

You may also be interested in these white papers

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Last viewed contents

Optimizing Protein Purification Conditions -

Optimizing Protein Purification Conditions -

Streamlining Affinity Analysis for Accelerated Biologics Development and Production - High-throughput and assay versatility for rapid development and qualification of biopharmaceuticals

Streamlining Affinity Analysis for Accelerated Biologics Development and Production - High-throughput and assay versatility for rapid development and qualification of biopharmaceuticals

Optimizing Kinetics Assays to Prevent Avidity Effects - Robust experimental design avoids artefacts in the measurement of binding kinetics and affinity

Optimizing Kinetics Assays to Prevent Avidity Effects - Robust experimental design avoids artefacts in the measurement of binding kinetics and affinity

Now ready - Easy Bispecific Antibody Evaluation - Analyze specific binding of bsAbs in addition to IgG titer in a single high-throughput assay

Now ready - Easy Bispecific Antibody Evaluation - Analyze specific binding of bsAbs in addition to IgG titer in a single high-throughput assay

How to purify and analyze your antibodies efficiently - All the chromatography methods and practical tips to simplify and reduce the costs of your processes

How to purify and analyze your antibodies efficiently - All the chromatography methods and practical tips to simplify and reduce the costs of your processes

Advance Lot Release and In-process Testing of Biologics in QC - Comprehensive technical and service support for Octet® users in GxP environments

Advance Lot Release and In-process Testing of Biologics in QC - Comprehensive technical and service support for Octet® users in GxP environments

Billion-Dollar Deal for Cancer Antibody: BioNTech and Bristol Myers Squibb Join Forces - "...an asset with significant potential for transforming the standard of care for patients with solid tumors"

Billion-Dollar Deal for Cancer Antibody: BioNTech and Bristol Myers Squibb Join Forces - "...an asset with significant potential for transforming the standard of care for patients with solid tumors"

Structural basis of the function of therapeutic antibodies in cancer immunotherapy elucidated - New study shows how the single-molecule organization of receptors in the cellular context determines the function of antibodies

Structural basis of the function of therapeutic antibodies in cancer immunotherapy elucidated - New study shows how the single-molecule organization of receptors in the cellular context determines the function of antibodies

Antibody discovered that blocks almost all known HIV variants in neutralization assays - The discovery potentially opens up new perspectives for the prevention and treatment of HIV infections

Antibody discovered that blocks almost all known HIV variants in neutralization assays - The discovery potentially opens up new perspectives for the prevention and treatment of HIV infections

Calypso Biotech SA - Plan-les-Ouates / Geneva, Switzerland

Calypso Biotech SA - Plan-les-Ouates / Geneva, Switzerland

Merck Life Science KGaA - Darmstadt, Germany

Merck Life Science KGaA - Darmstadt, Germany

Bio-Rad Laboratories Ltd. - Watford, United Kingdom

Bio-Rad Laboratories Ltd. - Watford, United Kingdom